| 商品名称 | Zavicefta |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Pneumonia, Bacterial;Soft Tissue Infections;Pneumonia;Urinary Tract Infections;Gram-Negative Bacterial Infections |
|---|
| 通用名/非专利名称 | ceftazidime;avibactam |
|---|
| 活性成分 | avibactam sodium;ceftazidime pentahydrate |
|---|
| 产品号 | EMEA/H/C/004027 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Authorised |
|---|
| ATC编码 | J01DD52 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | No |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2016/06/23 |
|---|
| 上市许可开发者/申请人/持有人 | Pfizer Ireland Pharmaceuticals Unlimited Company |
|---|
| 人用药物治疗学分组 | Antibacterials for systemic use |
|---|
| 兽用药物治疗学分组 | |
|---|
| 审评意见日期 | 2016/04/28 |
|---|
| 欧盟委员会决定日期 | 2025/05/20 |
|---|
| 修订号 | 20 |
|---|
| 治疗适应症 | Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections: Complicated intra-abdominal infection (cIAI) Complicated urinary tract infection (cUTI), including pyelonephritis Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP) Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2018/06/14 |
|---|
| 最后更新日期 | 2025/11/14 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/zavicefta-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta |
|---|